Human Recombinant Insulin Market Value Projected to Expand by 2018-2026

0

According to the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): 2016 report, the insulin market including human recombinant insulin largely contributes around 40 local manufacturers, with largely local markets apart from three largest global insulin manufactures: Novo Nordisk A/S, Sanofi S.A. and Eli Lilly and Company. Furthermore, various manufacturers offer a recombinant analog of human insulin-like growth factor that has been specifically engineered for the research and industrial cell culture market, providing a consistent, compliant, and reliable alternative to recombinant insulin. Such manufacturers include: Merck KGaA, Thermo Fisher Scientific, Inc., among others. These manufacturers offers recombinant human insulin analogue products as a raw material or blended with custom media formulations for small scale process development and commercial biomanufacturing applications. Launch of biosimilar and other insulin products and research for recombinant insulin products is expected to drive growth of the market during the forecast period.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1797

Moreover, rising diabetes population, worldwide combined with increasing research and development (R&D) activities by various government and private organizations in human insulin development is expected to boost growth of the human recombinant insulin market in the near future.

Efficient diabetes management and ease of use creates need for advancements in current solutions of both insulin and its delivery systems thereby, offering reduced patient discomfort. Glucose Responsive Insulin (GRI) or smart insulin is a novel technology for people with diabetes, which works by automatically reacting to blood sugar fluctuations in body and responds to changing blood glucose levels. The lower or higher blood sugar levels are lead to release of more or less insulin, respectively. Smart insulin decreases the number of regular blood tests required and also minimizes the number of daily dose of insulin injections. Researchers from the University of North Carolina have been working on a smart insulin patch. For instance, in 2015, researchers reported that, smart insulin patch can use a micro-needles system to automatically detect high blood glucose levels and administer insulin appropriately.

Key players operating in human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.

Key players in the human recombinant insulin market are implementing inorganic growth strategies to develop and introduce smart insulin technology in the market. For instance, in February 2016, Eli Lilly and Company acquired Glycostasis, Inc., a startup company engaged in developing smart insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart insulin’ technology.

Market Dynamics

Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. According to the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): 2016 report, global insulin market is largely dominated by three pharmaceutical companies: Novo Nordisk A/S, Sanofi S.A. and Eli Lilly and Company. Furthermore, Southeast Asia and Latin America accounts with higher number of smaller human recombinant insulin manufactures, than other regions.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1797

Detailed Segmentation: Global Human Recombinant Insulin Market, By Product Type: Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, Premixed Human Insulin, Global Human Recombinant Insulin Market, By Brand: Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, Others,. Global Human Recombinant Insulin Market, By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

Share.

About Author

Richard is a science and space enthusiast who aims to excel in the field, especially in human anatomical studies. He curates quality pieces for Ace Newz in the science genre.

Comments are closed.